A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...

Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate ...

More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

Introducing baked eggs to infants aged 4–6 months and maintaining daily intake for six months significantly improves ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...

Joya Griffin, DVM, DACVD, discusses the concept of ‘food as medicine’ and how prescription diets can help restore the skin’s ...

ORLANDO -- A novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, ...